Trabelsi Saoussen, Brahim Dorra H'mida-Ben, Ladib Mohamed, Mama Nadia, Harrabi Imed, Tlili Kalthoum, Yacoubi Mohamed Tahar, Krifa Hedi, Hmissa Sihem, Saad Ali, Mokni Moncef
Department of Cytogenetics, Molecular genetics and Reproductive Biology, Farhet Hached University Hospital, Sousse, Tunisia E-mail :
Asian Pac J Cancer Prev. 2014;15(20):8753-7. doi: 10.7314/apjcp.2014.15.20.8753.
Glioma is a heterogeneous central nervous system (CNS) tumor group that encompasses different histological subtypes with high variability in prognosis. The lesions account for almost 80% of primary malignant brain tumors. The aim of this study is to extend our understanding of the glioma epidemiology in the central Tunisian region.
We analyzed 393 gliomas recorded in cancer registry of central Tunisia from 1993 to 2012. Crude incidence rates (CR) and world age-standardized rates (ASR) were estimated using annual population data size and age structure. Statistic correlations were established using Chi-square and Kaplan-Meier test.
Tunisian glioma patients were identified with a mean age at diagnosis of 48 years and 1.5 sex ratio (male/female). During the 19 years period of study the highest incidence value was observed in male group between 1998 and 2002 (CR: 0.28, ASR: 0.3). Incidence results underline increasing high grade glioma occurring in the adulthood in the last period (2007-2012). Median survival was 27 months, with 1-, 2- and 5-year survival rates of 42%, 30% and 26%, respectively. Survival was greater in patients with younger age, lower tumor grade, infratentrial tumor location and undergoing a palliative treatment.
This central Tunisia gliomas registry study provides important information that could improve glioma management and healthcare practice.
胶质瘤是一组异质性的中枢神经系统(CNS)肿瘤,包含不同的组织学亚型,预后差异很大。这些病变占原发性恶性脑肿瘤的近80%。本研究的目的是扩展我们对突尼斯中部地区胶质瘤流行病学的认识。
我们分析了1993年至2012年突尼斯中部癌症登记处记录的393例胶质瘤病例。使用年度人口数据规模和年龄结构估计粗发病率(CR)和世界年龄标准化率(ASR)。使用卡方检验和卡普兰-迈耶检验建立统计相关性。
突尼斯胶质瘤患者确诊时的平均年龄为48岁,男女比例为1.5。在19年的研究期间,1998年至2002年男性组的发病率最高(CR:0.28,ASR:0.3)。发病率结果强调了在最后阶段(2007 - 2012年)成年期发生的高级别胶质瘤有所增加。中位生存期为27个月,1年、2年和5年生存率分别为42%、30%和26%。年龄较小、肿瘤分级较低、幕下肿瘤位置且接受姑息治疗的患者生存期更长。
这项突尼斯中部胶质瘤登记研究提供了重要信息,可改善胶质瘤的管理和医疗实践。